{"name":"Immunitor LLC","slug":"immunitor-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Daily oral dose of hepcortespenlisimut-L","genericName":"Daily oral dose of hepcortespenlisimut-L","slug":"daily-oral-dose-of-hepcortespenlisimut-l","indication":"Chronic hepatitis C infection (HCV)","status":"phase_2"},{"name":"V7","genericName":"V7","slug":"v7","indication":"HIV infection (therapeutic vaccine in treatment-experienced patients)","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"atherosclerosis vaccine","genericName":"atherosclerosis vaccine","slug":"atherosclerosis-vaccine","indication":"Atherosclerosis (cardiovascular disease prevention and progression reduction)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"hepcortespenlisimut-L","genericName":"hepcortespenlisimut-L","slug":"hepcortespenlisimut-l","indication":"Treatment of iron overload in patients with beta-thalassemia major","status":"phase_3"}]}],"pipeline":[{"name":"Daily oral dose of hepcortespenlisimut-L","genericName":"Daily oral dose of hepcortespenlisimut-L","slug":"daily-oral-dose-of-hepcortespenlisimut-l","phase":"phase_2","mechanism":"Hepcortespenlisimut-L is an oral therapeutic vaccine that stimulates immune responses against hepatitis C virus (HCV) antigens to enhance viral clearance.","indications":["Chronic hepatitis C infection (HCV)"],"catalyst":""},{"name":"V7","genericName":"V7","slug":"v7","phase":"phase_3","mechanism":"V7 is an immunotherapeutic vaccine designed to stimulate the immune system against HIV infection.","indications":["HIV infection (therapeutic vaccine in treatment-experienced patients)"],"catalyst":""},{"name":"atherosclerosis vaccine","genericName":"atherosclerosis vaccine","slug":"atherosclerosis-vaccine","phase":"phase_3","mechanism":"An immunotherapeutic vaccine that stimulates the immune system to recognize and attack oxidized lipoproteins and atherosclerotic plaques.","indications":["Atherosclerosis (cardiovascular disease prevention and progression reduction)"],"catalyst":""},{"name":"hepcortespenlisimut-L","genericName":"hepcortespenlisimut-L","slug":"hepcortespenlisimut-l","phase":"phase_3","mechanism":"Hepcortespenlisimut-L is a recombinant human prohepcidin analog that stimulates the production of hepcidin, a hormone that regulates iron metabolism.","indications":["Treatment of iron overload in patients with beta-thalassemia major"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"phase_2":1,"phase_3":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}